Re: RESEARCH - Treatment of RA patients with abatacept and MTX

[Guest guest]

>

> J Rheumatol. 2006 Apr;33(4):681-9. Epub 2006 Mar 1.

>

>

> Treatment of rheumatoid arthritis patients with abatacept and

methotrexate

> significantly improved health-related quality of life.

>

>

> Emery P, Kosinski M, Li T, M, GR, Becker JC,

Blaisdell B,

> Ware J Jr, Birbara C, AS.

>

> OBJECTIVE: This study examined the effect of abatacept, a

costimulation

> modulator, on the health-related quality of life (HRQOL) of

patients with

> rheumatoid arthritis (RA). METHODS: Three hundred thirty-nine

patients with

> RA on a background of methotrexate (MTX), who participated in a

multicenter,

> double-blind, placebo-controlled trial, were randomized to

abatacept 2

> mg/kg, abatacept 10 mg/kg, or placebo. HRQOL was assessed at

pretreatment,

> and at 3, 6, and 12 months posttreatment using the SF-36 Health

Survey

> (SF-36). Changes in SF-36 scores from baseline to 12 months were

compared

> across treatment and placebo groups to examine HRQOL benefits of

abatacept.

> A link between American College of Rheumatology improvement and

changes in

> SF-36 scores was established to demonstrate the association

between HRQOL

> outcomes and clinical response. RESULTS: After 12 months of

treatment,

> patients randomized to abatacept 10 mg/kg showed significantly

better HRQOL

> outcomes overall versus patients randomized to placebo (MANOVA F =

4.71, p <

> 0.001) or to abatacept 2 mg/kg (MANOVA F = 1.97, p = 0.05).

Differences in

> SF-36 change scores between abatacept 10 mg/kg and placebo groups

reached

> statistical significance on all 8 domain scales, the 2 summary

measures, and

> the SF-36 utility index (SF-6D). Differences in SF-36 change

scores between

> abatacept 10 mg/kg and abatacept 2 mg/kg reached statistical

significance on

> 5 of the 8 domain scales, the physical summary measure, and the SF-

6D.

> Improvement in HRQOL was highly related to clinical response.

>

> CONCLUSION Abatacept 10 mg/kg plus MTX demonstrated a stronger

HRQOL

> response than placebo plus MTX. The abatacept 2 mg/kg arm showed a

very weak

> and transient response.

>

> PMID: 16568505

>

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

cmd=Retrieve & db=pubmed & dopt=Abstract & list_uids=16568505

>

>

>

> Not an MD

>

> I'll tell you where to go!

>

> Mayo Clinic in Rochester

> http://www.mayoclinic.org/rochester

>

> s Hopkins Medicine

> http://www.hopkinsmedicine.org

>

[Guest guest]

Thankyou for your reasearch,i find it very helpful.

>

> J Rheumatol. 2006 Apr;33(4):681-9. Epub 2006 Mar 1.

>

>

> Treatment of rheumatoid arthritis patients with abatacept and

methotrexate

> significantly improved health-related quality of life.

>

>

> Emery P, Kosinski M, Li T, M, GR, Becker JC,

Blaisdell B,

> Ware J Jr, Birbara C, AS.

>

> OBJECTIVE: This study examined the effect of abatacept, a

costimulation

> modulator, on the health-related quality of life (HRQOL) of

patients with

> rheumatoid arthritis (RA). METHODS: Three hundred thirty-nine

patients with

> RA on a background of methotrexate (MTX), who participated in a

multicenter,

> double-blind, placebo-controlled trial, were randomized to

abatacept 2

> mg/kg, abatacept 10 mg/kg, or placebo. HRQOL was assessed at

pretreatment,

> and at 3, 6, and 12 months posttreatment using the SF-36 Health

Survey

> (SF-36). Changes in SF-36 scores from baseline to 12 months were

compared

> across treatment and placebo groups to examine HRQOL benefits of

abatacept.

> A link between American College of Rheumatology improvement and

changes in

> SF-36 scores was established to demonstrate the association

between HRQOL

> outcomes and clinical response. RESULTS: After 12 months of

treatment,

> patients randomized to abatacept 10 mg/kg showed significantly

better HRQOL

> outcomes overall versus patients randomized to placebo (MANOVA F =

4.71, p <

> 0.001) or to abatacept 2 mg/kg (MANOVA F = 1.97, p = 0.05).

Differences in

> SF-36 change scores between abatacept 10 mg/kg and placebo groups

reached

> statistical significance on all 8 domain scales, the 2 summary

measures, and

> the SF-36 utility index (SF-6D). Differences in SF-36 change

scores between

> abatacept 10 mg/kg and abatacept 2 mg/kg reached statistical

significance on

> 5 of the 8 domain scales, the physical summary measure, and the SF-

6D.

> Improvement in HRQOL was highly related to clinical response.

>

> CONCLUSION Abatacept 10 mg/kg plus MTX demonstrated a stronger

HRQOL

> response than placebo plus MTX. The abatacept 2 mg/kg arm showed a

very weak

> and transient response.

>

> PMID: 16568505

>

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

cmd=Retrieve & db=pubmed & dopt=Abstract & list_uids=16568505

>

>

>

> Not an MD

>

> I'll tell you where to go!

>

> Mayo Clinic in Rochester

> http://www.mayoclinic.org/rochester

>

> s Hopkins Medicine

> http://www.hopkinsmedicine.org

>